FDA
-
-
-
-
-
-
-
Krystal Biotech reports gene therapy delivers CFTR protein to CF patients
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Krystal Biotech (KRYS)
-
-
-
-
-
-
-
Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results
-
-
-
-
-
-
-
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
-
-
-
-
-
-
-
Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025
-
-
-
-
-
-
-
Krystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
-
-
-
-
-
-
-
Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

